Compare Crispr Therapeutics AG (CRSP) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs ABRDN Physical Gold Shares ETF — how do they compare? Crispr Therapeutics AG trades at $53.41 (market cap $4.88B), while ABRDN Physical Gold Shares ETF trades at $39.88 (market cap $7.03B). The key difference: ABRDN Physical Gold Shares ETF is the larger of the two by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| CRSP | SGOL | |
|---|---|---|
Market Cap | $4.88B | $7.03B |
Volume | 2,861,747 | 2,350,550 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $74.92 | $51.41 |
52-Week Low | $44.34 | $37.54 |
Typical Hold Time | 77 Days | 57 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
SGOL trades at $39.81 with a 2.02% daily gain amid mixed technical signals. The overall technical picture remains bearish with moving averages indicating selling pressure, though oscillators show neutral momentum. Recent news highlights gold's sensitivity to Treasury yields and Federal Reserve policy expectations, with prices facing headwinds from rising rates but finding some support from inflation concerns and geopolitical tensions.
The outlook for SGOL is cautious with technical indicators favoring bearish momentum, while fundamental drivers depend on macroeconomic factors. Investment opportunities exist if inflation persists or geopolitical risks escalate, but risks include further rate hikes and dollar strength. Wall Street sentiment is divided with some analysts projecting declines to $4,100 while others see potential for $5,000 by mid-2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
